Home › NCT07600736

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy

A Phase 1b/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 Administered to Pediatric and Young Adult Participants With KCNT1-Related Epilepsy

Who can join

1 Month – 21 Years · All sexes

Inclusion Criteria:

* Aged 1 month to \<22 years
* Clinician-confirmed diagnosis of KCNT1-related epilepsy
* Has an average of at least 4 countable motor seizures per week
* Is taking no more than 6 antiseizure medications (ASM) and is able to keep stable doses of ASMs for the duration of Part 1 or Part 2

Exclusion Criteria:

* Is currently taking phenytoin, carbamazepine, stiripentol, or quinidine
* Has a medical condition that, in the opinion of the investigator, would limit the participant's ability to participate in the study or might compromise participant safety or interfere with evaluation of the study drug.

About the study

This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy

What is being tested

• ABS-1230 (drug)
• Placebo (drug)

Sponsor: Actio Biosciences, Inc. · Participants: 55 · Started: May 18, 2026

Contact the study team

• Medical Director Actio Biosciences, Inc. · Phone: +1 (858) 682-4042

Official record on ClinicalTrials.gov — NCT07600736

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.